Buscar resultados de ensayos clínicos
Lymphoma, T-Cell - 77 Studies Found
Estado | Estudiar |
Not yet recruiting |
Nombre del estudio: 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma Condición: Lymphoma, T-Cell, Peripheral Fecha: 2017-02-09 Intervenciones: Device: 18F-FDG PET/ CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Not yet recruiting |
Nombre del estudio: Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma Condición: Lymphoma, T-Cell, Peripheral Fecha: 2017-02-09 Intervenciones: Device: 18F-FDG PET/CT 18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients |
Completed |
Nombre del estudio: Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-09-09 Intervenciones:
|
Completed |
Nombre del estudio: Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma Condición: Lymphoma, T-Cell Fecha: 2007-01-03 Intervenciones: Drug: Concurrent Radiotherapy (RT)/cisplatin, VIPD |
Completed |
Nombre del estudio: Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2005-09-13 Intervenciones: Drug: ONTAK (denileukin difitox, DAB389IL-2) |
Recruiting |
Nombre del estudio: T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma Condición: Lymphoma, T-Cell, Peripheral Fecha: 2010-06-10 |
Recruiting |
Nombre del estudio: Alemtuzumab and CHOP in T-cell Lymphoma Condición: Lymphoma, T-Cell, Peripheral Fecha: 2008-02-14 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas Condición: Lymphoma, T-Cell Fecha: 2014-06-05 Intervenciones: Drug: MLN9708 |
Completed |
Nombre del estudio: A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2011-11-29 Intervenciones: Drug: Quisinostat, 12 mg Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1 |
Completed |
Nombre del estudio: CPG 7909 in Patients With Cutaneous T-Cell Lymphoma Condición: Lymphoma, T-Cell, Cutaneous Fecha: 2002-08-08 Intervenciones:
|